A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTI-CENTER STUDY TO EVALUATE THE SAFETY AND EFFICACY OF THE ORAL, GUT-RESTRICTED ALPHA4BETA7 INTEGRIN PEPTIDE ANTAGONIST PN-943 IN PATIENTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS: RESULTS FROM THE IDEAL STUDY

Scott Plevy  ¹     Bruce E. Sands  ²     Julian Panés  ³     Geert R. D'Haens  ⁴     Vipul Jairath  ⁵     Brian G. Feagan  ⁶     Suneel Gupta     C. C. Hwang     Scott Lee     Alessandro Armuzzi     Walter Reinisch     Stefan Schreiber     William J. Sandborn    
¹ Protagonist Therapeutics, Newark, United States
² Icahn School of Medicine at Mount Sinai, New York, United States
³ Hospital Clínic Barcelona, Barcelona, Spain
⁴ AMC Amsterdam Inflammatory Bowel Disease Centre - Academic Medical Center, AMC Amsterdam Inflammator, Amsterdam, Netherlands
⁵ Alimentiv Inc., London, Canada
⁶ The University of

Session
Clinical trials in ulcerative colitis I

Conference
UEG Week 2022

Citation
United European Gastroenterology Journal 2022; 10 (Supplement 8)